retatrutide clinical trial south korea VisualAbstract: Retatrutide reduces body weight by 17.5% in patients with obesity Eli Lilly's next-generation obesity treatment

After 68 weeks, participants receiving a 2.4 mg weekly semaglutide dose experienced a 49% reduction in C-reactive protein (CRP), while those on a 1 mg weekly dose saw a 42% reduction compared to placebo

doi: 10.1210/en.2015-1750 150 ChowLSMashekDGWangQShepherdSOGoodpasterBHDubJJ

Reuters (2026)

The 20mg vial is the middle option, halving the number of vials and certificates to reconcile against a 10mg-only supply while keeping the in-use window manageable

Energy levels typically improve substantially after the initial adjustment period

Glucagon-Like Peptide-1 Analog, Liraglutide, Improves Visceral Sensation and Gut Permeability in Rats